123P - A retrospective study in Chinese patients: Is there a role of nanoparticle albumin bound paclitaxel in advanced NSCLC?

Date 07 May 2017
Event ELCC 2017
Session Poster Display Session
Topics Thoracic Malignancies
Non-Small Cell Lung Cancer
Presenter Yixiang Zhu
Citation Annals of Oncology (2017) 28 (suppl_2): ii28-ii51. 10.1093/annonc/mdx091
Authors Y. Zhu1, P. Xing1, L. Shan2, S. Chen3, X. Hao1, J. Li1
  • 1Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN
  • 2Cancer Hospital Shanghai Medical University, Shanghai/CN
  • 3Bejing Tongren Hospital Capital Medical University, Beijing/CN



We aimed to report the safety and short-term efficacy of nanoparticle albumin bound paclitaxel (Nab-PTX) in advanced non-small cell lung cancer (NSCLC) in Chiina as a second line and later treatment, and explored its efffcacy affected by previous paclitaxel treatment wether or not.


Advanced NSCLC patients who failed in prior treatment and received weekly Nab-PTX regimen on days 1, 8 (a dose of 130 mg/m2/week) treatment were included. The primary efficacy endpoint was progression-free survival (PFS). Toxicity was evaluated with NCI-CTCAE 3.0.


A total of 98 patients at the Cancer Institute & Hospital of the Chinese Academy of Medical Sciences (Beijing, China) between June 2010 and July 2015 were enrolled. The median PFS and overall survival (OS) were 4.34 months (95% CI 3.508 to 5.165 months) and 11.73 months (95% CI 9.211 to 14.247 months), respectively. PFS was no significant difference between patients with previous paclitaxel treatment and without previous paclitaxel treatment (median, 4.11 versus 4.53 months, respectively, p = 0.195). OS was also no significant difference between the two arms (median, 9.69 versus 14.62 months, respectively, p = 0.190). The objective responses rate (ORR) and disease control rate (DCR) of all patients were 22.4% and 74.5%, respectively. The ORR and DCR were 23.0% and 70.5%, respectively in one arm with previous paclitaxel treatment, while in another arm without previous paclitaxel treatment, the results were 21.6% and 81.1%. No significant difference in ORR (p = 0.533) and DCR (p = 0.244) between the two arms. Grade 3 or higher adverse events (AEs) of all patients was neutropenia (25.5%), leukopenia (12.4%), peripheral neuropathy (5.1%), myalgia/arthralgia (5.1%), anaemia (3.1%), and fatigue (1.0%), respectively.


The Nab-PTX was effective and well tolerated as second line or later treatment in advanced NSCLC patients. Even used paclitaxel treatment previously did not affect the efficacy and PFS of Nab-PTX.

Clinical trial identification

Preview and Finish

Legal entity responsible for the study

Junling Li


Junling Li


All authors have declared no conflicts of interest.